# Impact of Cumulative Exposure to Respiratory Viruses after Allogeneic Hematopoietic Cell Transplantation

> **NIH NIH K23** · SEATTLE CHILDREN'S HOSPITAL · 2020 · $185,095

## Abstract

PROJECT SUMMARY
This proposal describes a five-year research training program that will allow the candidate to achieve his
long-term goal of becoming an independent clinically-oriented academic researcher, focusing on respiratory
viral infections (RVIs) in immunocompromised (IC) hosts. His objective is to improve hematopoietic cell
transplantation (HCT) outcomes by improving the understanding of RVI disease burden and the association
with antibiotic use. He will apply the knowledge gained through this proposal to develop therapeutic and
preventive strategies that mitigate the disease burden and complications of RVI in IC hosts. This proposal
builds upon his clinical training in infectious diseases as well as epidemiologic and biostatistical methods for
clinical research in this field. He provides a detailed plan to enhance his knowledge of healthcare services,
molecular virology and conducting prospective studies. This proposal incorporates the expertise of an
outstanding group of mentors, including experts in transplant infectious diseases, epidemiology, statistics,
antimicrobial stewardship, healthcare services, and laboratory medicine, who are dedicated to ensuring the
success of this project and the development of his career as an independent clinical researcher.
The first aim of this proposal involves a large retrospective cohort of allogeneic HCT recipients to determine
the burden of multiple (concurrent or sequential) RVIs on airflow obstruction, fungal and bacterial pulmonary
infections, mortality and healthcare resource utilization after HCT. Using a multiplex quantitative PCR, he will
test a hypothesis that multiple RVIs have a dose-dependent association with increased risk of these
outcomes. His second aim will examine whether specific or cumulative antibiotic exposure is associated with
increased risk of respiratory viral disease progression. As is the case in first aim, a large cohort of patients
will allow him to analyze these relationships while adjusting for multiple clinical covariates. The third aim will
characterize the incidence and disease spectrum of RVI as well as antibiotic use following new respiratory
symptoms late after allogeneic HCT. Capturing data regarding RVI and antibiotic use will be optimized by
utilizing home-based self-collected nasal swabs and prospective monitoring.
By accomplishing the aims in this proposal, he will address critical gaps in our knowledge of the contribution
of multiple RVIs to disease burden in HCT recipients and the utility of multiplex molecular testing. Given that
new antiviral therapeutics and vaccines are on the horizon, understanding the relative significance of
multiple RVIs will provide the rationale to develop “multi”-target antiviral agents as well as therapeutic and
preventive strategies. In addition, the clarification of the link between RVI and antibiotic use will inform
optimized antibiotic strategies using viral diagnostics. Ultimately, this proposal will allow him to build a...

## Key facts

- **NIH application ID:** 9850211
- **Project number:** 5K23AI139385-02
- **Recipient organization:** SEATTLE CHILDREN'S HOSPITAL
- **Principal Investigator:** Chikara Ogimi
- **Activity code:** K23 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $185,095
- **Award type:** 5
- **Project period:** 2019-01-15 → 2023-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9850211

## Citation

> US National Institutes of Health, RePORTER application 9850211, Impact of Cumulative Exposure to Respiratory Viruses after Allogeneic Hematopoietic Cell Transplantation (5K23AI139385-02). Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/grant/nih/9850211. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*